INTRODUCTION
Drug resistance is a major cause of cancer treatment failure. Non-responsive patients do not benefit from the treatment but may still suffer from the side effects. A biomarker predicting tumor response to a drug will enhance the ability to individualize patient treatment, thus making development of cancer therapies more effective and safe.
TNFα-related apoptosis inducing ligand (TRAIL) induces apoptosis through death receptors (DRs) 4 and/or 5 expressed on the surface of target cells (1) . Compared to TNFα, which was associated with severe toxicities after systemic administration, TRAIL appears to selectively kill cancer cells while leaving the normal cells largely unaffected (2, 3) .
Recombinant human TRAIL (rhTRAIL) and its agonistic antibodies are being clinically evaluated as a potential cancer therapy (4) . However, some tumor cells, including those from breast cancer, are found to be resistant to TRAIL-induced apoptosis via intrinsic or acquired mechanisms (5) (6) (7) (8) . There is an unmet need for a biomarker that can predict tumor response to TRAIL-related therapies.
The most common approach in identifying biomarker is a top-down approach where knowledge of the putative target of a treatment is used to look for alterations in the target itself or related signaling components that render the treatment effective or ineffective. By this approach, it has been shown that TRAIL-resistance is associated with genetic defects in TRAIL signaling components, including loss of functional DR4 and DR5 on the cell surface (7, 8) , O-glycosylation status (9) , and elevated expression of antiapoptotic proteins c-FLIP (10), Bcl-2 (1) and IAP family proteins (11) . However, these mechanisms are not generally applicable to different cancer types. In this study, we took a universal bottom-up approach that is based on measuring the response in cell lines and correlating differences in their gene
MATERIALS AND METHODS
Cell lines and reagents. The NCI60 panel of human cancer cell lines used for the testing of TRAIL sensitivity were maintained and tested for identity and mycoplasma at the US National Cancer Institute (http://dtp.nci.nih.gov). Human breast cancer cell lines including HCC1428 and HCC1143 were obtained from the American Type Culture Collection (ATCC), where the cell lines were tested and authenticated by growth rate, morphology, isoenzymology, short tandem repeat (STR) profiling, and mycoplasma testing (www.ATCC.org). All cell lines were cultured per vendors' recommendation and tested for sensitivity to TRAIL within 3 months from the date of purchase from ATCC. Recombinant human TNF-related apoptosis inducing ligand (rhTRAIL) was from R & D systems, which contains 168 amino acids corresponding to the extracellular domain of human TRAIL (Val114 -Gly281), expressed by E. coli and purified as a homotrimeric protein.
NCI60 anticancer drug screen. The NCI60 panel anticancer drug screen was performed at the National Cancer Institute (NCI)/NIH Developmental Therapeutics Program (16, 17) (see details at http://dtp.nci.nih.gov/branches/btb/ ivclsp.html). Briefly, cells were seeded in 96-well plates at plating densities ranging from 5000 to 40000 cells/well depending on the doubling time of individual cell lines. After 24 h incubation, some of the wells were processed to determine a time zero density. To the rest of the plates, rhTRAIL was added at five different doses (6, 12, 25, 50 , or 100 ng/mL). Plates were incubated for another 24 h, then fixed with trichloroacetic acid (TCA) and stained with sulfo rhodamine B (SRB), and measured for absorbance at 515 nm SRB binds as a measure of cell. SRB binds on protein basic amino acid residues for measuring relative total protein amount and cell viability.
Growth inhibition is calculated relative to cells without drug treatment and the time zero control. The use of a time zero control allows the determination of cell killing as well as net growth inhibition. Growth inhibition of 50 % (GI50), which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation, is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50 using absorbance at 515 nm at time zero (Tz), in the absence of TRAIL (C), and in the presence of TRAIL (Ti).
Predictor development based on NCI60 gene expression data. Gene expression profiles of 58 of the 60 cell lines in the NCI60 panel were obtained from Shankavaram (18) . First, the gene expression measurements were logit normalized i.e. for each array the transformation logit = log[(x -background)/(saturation -x)] was performed followed by a Z-transformation to mean zero and standard deviation one and dChip expression index was calculated by summarizing the 11 independent perfect match probes into one probeset corresponding to one gene. The resulting expression value for each gene in each of the 58 cell lines was then correlated to the measured GI50 values in the same cell lines to look for genes that can explain the observed difference in growth inhibition i.e. Correlation=cor(expression, -logGI50). Genes with a Pearson correlation above 0.25 were considered potential markers of response and retained as a response profile for TRAIL. To reduce the number of false positive markers passing the Pearson correlation cutoff, we applied a statistical bootstrapping filter and a biological relevance filter that mapped sub-networks of markers known to interact, similar to the approach described by Chuang (18) .
Finally, we selected the number of genes that performed best in predicting the growth inhibition/apoptosis in the training set of NCI60. All statistical analysis was performed in R (www.r-project.org) using the affy library of Bioconductor (www.bioconductor.org).
Prediction of TRAIL sensitivity in cancer cell lines. The identified gene signature from the NCI60 training set was evaluated in two independent test sets consisting of 119 human cancer cell lines from different cancer types (9) and 18 human breast cancer cell lines, respectively, based on gene expression data from Wagner et al. (9) and Hoeflich et al. (19) . In addition, we examined the gene signature for prediction of TRAIL sensitivity in four independent cohorts of human breast tissues, including two cohorts of normal breast tissues (GEO accession numbers: GSE20437 and GSE9574) and two cohorts of breast tumor tissues (GSE20194 and GSE12093) (http://wwww.ncbi.nlm.nih.gov/geo). After logit normalization and dChip expression index calculation of array data from independent data sets (cell lines or primary tissues), the expression value of each gene in the response profile for TRAIL were averaged to yield a quantitative score of TRAIL sensitivity on a scale from 0 to 100 based on the lowest average expression (Min) and the highest average expression (Max). Statistical significance of the prediction was calculated as Pearson product moment correlation between the prediction scores of cell lines and their measured TRAIL sensitivity (GI50). When resistant cell lines were compared to sensitive cell lines, statistical significance was calculated using a Wilcoxon test. In some comparisons, the quantitative TRAIL sensitivity score was converted to a categorical prediction (sensitive or resistant) by applying a cutoff to the sensitivity score.
Using the above defined 0-100 gene expression scale, 50 or (Min+Max)/2 of a specific data set was used as a cutoff between TRAIL-resistant and TRAIL-sensitive cells. In the NCI60 Table 1 ). The results classify 60% (35/60) of the cell lines as highly or moderately sensitive (regarded as sensitive) with GI50 < 100 ng/mL. All other cell lines (40%, 25/60) exhibited < 20% growth inhibition in the presence of 100 ng/mL rhTRAIL after 24 h incubation and are being regarded as resistant (GI50 >100 ng/mL) in the following discussion. Next, the measured GI50 values were correlated with the genome wide gene expression data in each of the NCI60 cell lines using Pearson's analysis. By applying a 0.25 cutoff value of correlation coefficient (CC) for each gene and a biological relevance filter, we identified 91 probesets corresponding to 71 genes whose expressions were positively correlated with the measured TRAIL sensitivity, meaning that the 71 genes were systemically expressed at higher levels (~1 to 2.5 fold) in sensitive cell lines than resistant cell lines.
Trying progressively smaller subsets of the 71-gene predictor revealed that the performance drops when less than 71 genes are used ( Figure 2A ). We also identified 11 genes whose expression levels were systemically higher in TRAIL-resistant cell lines than in TRAILsensitive cell lines, including EEF1D, MAGED4, ADARB1, CSE1L, EVL, PAICS, RAD51C, GATA3, SSRP1, MARCKSL1, and LOC100272216. However, inclusion of these genes with opposite sign in the prediction of TRAIL sensitivity did not improve the prediction accuracy in our test sets. The identified 71 genes were then used to predict TRAIL sensitivity in 58 of (Table 1 ). Higher prediction accuracy (>80%) was achieved for cancer cell lines derived from leukemia, CNS, melanoma, and breast carcinoma (Fig. 2B) . Figure 2C shows a heatmap of the 71 genes in 58 of the 60 cell lines for which we have gene expression data.
Thus, the upregulation of the 71 genes appears to constitute a predictor of TRAIL response in cancer cells (Table 2) . Validation on independent test of breast cancer cell lines. We (7, 8, 20) and others (5, 6, 21) have shown that TRAIL is potentially useful in treating breast cancers. However, a significant number of breast cancer cell lines were found to be resistant to TRAIL killing. We asked whether the 71-gene predictor could also be used to predict TRAIL sensitivity in breast cancer cells. Therefore, we investigated TRAIL sensitivity in a panel of 18 human breast cancer cell lines, including 9 cell lines tested for TRAIL sensitivity in our laboratory (MDA-MB-231, SKBR3, BT474, BT549, T47D, MDA-MB-468, MCF7, and HCC1143, HCC1428) (8) , of which 7 cell lines were also tested by Rahman et al (22) , and 9 additional cell lines tested by Rahman (AU-565, HCC1954, HCC1937, HS578T, MDA-MB-436, HCCC38, HCC1500, MDA-MB-453, BT20). Using the expression levels of the 71 genes, our calculation predicted that 44% (8/18) of the cell lines to be TRAIL sensitive and 56% (10/18) of the cell lines to be resistant ( (see Materials and Methods). The predicted TRAIL sensitivity is shown in Fig. 3D . All the normal breast tissues were found to express lower levels of the 71 genes, with average expression values below the cutoff 50 in each cohort, and then were predicted to be resistant to TRAIL. Of the breast tumors, 64% are predicted to be sensitive to TRAIL. Overall, normal breast tissues were predicted to be significantly less sensitive to TRAIL cytotoxicity than breast tumors (P-value < 2.2e-16). These results support not only the selectivity of TRAIL towards cancer cells but also the utility of the 71-gene signature in prediction of TRAIL sensitivity.
Involvement of interferon induced genes in TRAIL sensitivity. The identified 71 genes
fall into at least five distinct functional groups, including interferon (IFN) pathways, major histocompatibility complex (MHC), apoptosis, and those of less defined functions (Table 2) .
Thirteen genes were found to be IFN-related, including IFI41, IFI41, IFI44L, DDX60, MX1, G1P2, IFIH1, IRF9, IFI35, IFI27, IFI44, IFI30, IFIT3, and IFNGR1. Some of these genes have been shown to be directly upregulated in response to type I (e.g. IFN-α, IFN-β) and/or type II IFN (IFN-γ) in human cancer cells (23) . We sought to examine whether treatment with IFN could alter cellular response to TRAIL induced apoptosis. To this end, we randomly selected five cell lines from the NCI60 panel that were predicted to be TRAIL-resistant, including A549, SK-MEL-5, HT-29, K562, and 768-0. All five cell lines were confirmed to be resistant to TRAIL induced killing ( 
shown). The failure of IFN-γ in overcoming TRAIL resistance in some cell lines may reflect the difference in their genetic background and also suggest the involvement of other genes in regulation of TRAIL apoptosis pathways. By contrast, IFN-α had no synergy with TRAIL in the cell lines tested. The mechanism underlying the differential effects between IFN-γ and IFN-α is not clear, but it may be related to their difference in inducing caspase genes (24) .
Indeed, the IFN-γ enhanced cytotoxicity was correlated with an increase in apoptosis (Fig 4B) and caspase cleavage (Fig. 4C) , which was completely blocked by treatment with a general caspase inhibitor Z-VAD (Fig. 4D) . Consistent with our data, there are also reports that IFN-γ augmented TRAIL killing in colon (25) , bladder (26) , renal (27) , and gastric carcinomas (28) .
These data show that IFN-γ pathways play a critical role in modulating cellular sensitivity to TRAIL induced apoptosis.
Functional pathway analysis revealed various types of interactions between
MHC genes, interferon pathways, and TRAIL pathways (Supplement III). While the molecular mechanisms remain to be elucidated, the upregulation of IFN-γ regulated genes appears to constitute a critical determinant of TRAIL sensitivity. ( Fig. 3B & C) as well as primary breast tumors (Fig. 3D) . In the latter, the expression pattern of the 71 genes predicted normal breast tissues to be significantly less sensitive than breast tumors to TRAIL cytotoxicity. The 71 genes are expressed at a significantly higher level in TRAIL sensitive cells than resistant cells, suggesting that selecting patients whose tumor has this gene expression profile is likely to improve the odds of obtaining clinical benefit from this agent. A similar approach has been successfully used for targeted therapies such as Herceptin and Avastin, where patients are screened for Her2 or Ras mutant status (30) . In relation to TRAIL therapy, Wagner et al. (9) reported that the mRNA expression of the peptidyl O-glycosyltransferase GALNT14 was associated with a higher TRAIL sensitivity in certain cancer cell lines. We examined the mRNA expression of GALNT14 in the NCI60 panel and found no statistically significant difference between the most sensitive and most resistant cell lines in the NCI60 panel (data not shown). Araki et al. (31) recently proposed a 4-gene expression predictor (STK17B, SP140L, CASP8, and AIM1) for cellular sensitivity to a monoclonal antibody against TRAIL-R1 (DR4 mAb) and TRAIL using a training set of six colon cancer cell lines. CASP8 was also differentially expressed between TRAIL-resistant and TRAIL-sensitive cell lines in the NCI60 training set. However, the performance of prediction is unaffected by including CASP8 to the 71 genes (CC=0.73 without CASP8 and CC=0.73 with CASP8). The other genes are not differentially expressed in our dataset. We speculate that the differences in outcome may be due largely to the difference in mechanisms of action between TRAIL and TRAIL-R1 mAb. Although both agents share a downstream signaling pathway, it is generally agreed that TRAIL induces apoptosis through DR4 and/or DR5, while DR4 mAb only targets DR4. We have shown that the two death receptors are differentially regulated in cancer cells, which directly impacts on TRAIL sensitivity. The 71-gene signature produced a better prediction for TRAIL sensitivity in breast, leukemia, melanoma and CNS (Fig. 2B & 3B ) than in other cancer types such as NSCLC (not shown) and pancreatic (Fig. 3B ). This might be related to the following factors: 1) the difference in genetic background between cancer types; 2) the size of samples for each cancer type included in a test dataset; and 3) the discrepancy of TRAIL sensitivity for a specific cell line measured by different laboratories. For example, MDA-MB-468, MCF7, T47D breast cancer cell lines were shown to be TRAIL-resistant by several groups; however, they were shown to be TRAIL-sensitive by others (6, 8, 22) . This could be a result of cell line variation and/or a difference in the preparation of rhTRAIL protein used in the assays. Despite the same tissue origin, a cell line used in the gene expression analysis may not be identical to the one used for TRAIL sensitivity assay which could cause mismatch and a lowered prediction accuracy. Regardless, the performance of the 71-gene predictor could be improved by increasing the number of samples in a test dataset. (25), bladder (26) , renal (27) , and gastric carcinomas (28) . IFN-γ is likely to augment TRAIL-induced apoptosis through upregulation of caspase activity (Fig. 4) Fig. 1. TRAIL cytotoxicity in NCI60 panel. A-D Table 1 . (Table 1) was confirmed in all cell lines tested, which was overcome by combination with IFN-γ, but Interferon or viral induced (13)  IFI41, IFI44L, DDX60, MX1, G1P2, IFIH1, IRF9, IFI35, IFI27,  IFI44, IFI30, IFIT3, IFNGR1 MHC genes ( GI50 values are listed in Table 1 . 
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